AI Article Synopsis
Article Abstract
Objective: To investigate the molecular epidemiology of () isolated from patients in the Yellow River Delta region and to construct antibiotic resistance profiles in different genetic backgrounds.
Methods: Antibiotics susceptibility testing, staphylococcal protein A () typing and accessory gene regulator () typing were performed for all the 204 strains. Isolates with the positive gene and heterogeneous vancomycin-intermediate (hVISA) were subjected to multilocus sequence typing (MLST) and Staphylococcal chromosomal cassettes (SCC) typing.
Results: Thirty-nine MRSA strains were identified by gene. Twenty-two hVISA isolates including 9 MRSA and 13 methicillin-sensitive (MSSA) strains were confirmed, the rest isolates (n = 182) were vancomycin-susceptible (VSSA). 94.9% of MRSA and 63.6% of hVISA belonged to I. Fifty-seven distinct types including 5 novel types were mainly t309 (30.9%), t078 (11.8%) and t437 (11.8%). Fourteen sequence types (STs) containing 3 new STs were classified into 3 clone complexes (CCs) and 7 singletons among MRSA and hVISA isolates. Most MRSA isolates (87.2%) belonged to type Ⅳ SCC.
Conclusion: The predominant genotype among MRSA population was ST59-t437-I-IVa (53.8%), followed by ST72-t2431-I-IVF (15.4%). ST72 and CC5 (ST5/965/7197) were the most common hVISA clones. Both CC59 (ST59/7437) and ST72 clones were resistant to erythromycin and clindamycin among MRSA population. Strains of MSSA with phenotypic hVISA (MS-hVISA) exhibited a striking genetic diversity accompanied by the diversification of drug resistance patterns.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882971 | PMC |
| http://dx.doi.org/10.2147/IDR.S392908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation.
J Glob Antimicrob Resist
November 2024
Department of Hematology, Tianjin First Central Hospital, Tianjin, PR China.
Objective: The objective of this study was to investigate the cumulative fraction of response of various dosage regimens of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults.
Methods: Monte Carlo simulations were performed using previously published pharmacokinetic parameters and pharmacodynamic data to evaluate the efficacy of the simulated dosage strategies in terms of area under the concentration-time curve/minimum inhibitory concentration targets of tedizolid.
Results: According to the results of the Monte Carlo simulations, currently approved dosage regimens of tedizolid phosphate were effective in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by methicillin-susceptible S.
Reduced vancomycin susceptibility in Staphylococcus aureus clinical isolates: a spectrum of less investigated uncertainties.
BMC Infect Dis
October 2024
Medical Microbiology and Immunology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Background: Staphylococcus aureus clinical isolates with vancomycin MICs of 2 µg/ml have been associated with vancomycin therapeutic failure and the heterogenous vancomycin-intermediate S. aureus (hVISA) phenotype. While carriage of van genes has usually been associated with higher level of MIC and frank vancomycin resistance, the unrecognized risk of hetero-resistance is frequently underestimated.
View Article and Find Full Text PDFSingle-cell phenotypic profiling and backtracing exposes and predicts clinically relevant subpopulations in isogenic Staphylococcus aureus communities.
Commun Biol
October 2024
Centre for New Antibacterial Strategies (CANS) and Research Group for Host-Microbe Interactions, Department of Medical Biology, UiT - The Arctic University of Norway, Tromsø, Norway.
Isogenic bacterial cell populations are phenotypically heterogenous and may include subpopulations of antibiotic tolerant or heteroresistant cells. The reversibility of these phenotypes and lack of biomarkers to differentiate functionally different, but morphologically identical cells is a challenge for research and clinical detection. To overcome this, we present ´Cellular Phenotypic Profiling and backTracing (CPPT)´, a fluorescence-activated cell sorting platform that uses fluorescent probes to visualize and quantify cellular traits and connects this phenotypic profile with a cell´s experimentally determined fate in single cell-derived growth and antibiotic susceptibility analysis.
View Article and Find Full Text PDFStaphylococcus aureus response and adaptation to vancomycin.
Adv Microb Physiol
July 2024
Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark. Electronic address:
Antibiotic resistance is an increasing challenge for the human pathogen Staphylococcus aureus. Methicillin-resistant S. aureus (MRSA) clones have spread globally, and a growing number display decreased susceptibility to vancomycin, the favoured antibiotic for treatment of MRSA infections.
View Article and Find Full Text PDFRisk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate bacteremia.
Microbiol Spectr
August 2024
Division of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Article Synopsis
- The study looked at patients with a serious infection called hVISA who were treated with a medicine called vancomycin and found that a lot of them (78%) didn't get better.
- Older patients and those with serious health problems had a harder time improving compared to younger and healthier patients.
- Researchers discovered that age and how severe the infection was played big roles in whether the treatment worked or not, suggesting doctors should pay extra attention to these factors when treating hVISA infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!